[Effective measures against side effects by increasing ACNU dose for malignant glioma: effects on digestive organs].
Loading therapy consisting of the ACNU regimen was instituted as postoperative anticancer chemotherapy for malignant gliomas. The efficacy rate of the regimen was 25% at a dose of 3 mg/kg. A high incidence of hematological changes, such as leukopenia (neutropenia) and thrombocytopenia, were observed after chemotherapy. The former could be prevented by the administration of G-CSF, but platelet infusions were necessary in some patients for amelioration of thrombocytopenia. Gastroenterological symptoms, such as nausea and vomiting, were also frequently noted. Granisetron (Kytril), which is a recently developed selective competitive inhibitor of the 5-HT3 receptor, was used for the treatment of these adverse effects, and was found to be clinically effective.
Numa
Y
Y
Dept. of Neurosurgery, Kansai Medical University.
Kasai
H
H
Imahori
T
T
Tsuchida
T
T
Kawamoto
K
K
D000328:Adult; D000368:Aged; D000855:Anorexia / Q000139:chemically induced*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004359:Drug Therapy, Combination; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000473:pathology; D017829:Granisetron / Q000008:administration & dosage*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D015376:Nimustine / Q000008:administration & dosage* / Q000009:adverse effects*; D014839:Vomiting / Q000139:chemically induced
D017829:Granisetron; D016179:Granulocyte Colony-Stimulating Factor; D015376:Nimustine